Press Release (ePRNews.com) - NAPLES, Fla. - Mar 05, 2021 - Native Cardio, Inc. a cardiac medical device manufacturer located in Naples, FL, dedicated to developing medical devices to improve the outcomes of patients suffering from acute and chronic atrial fibrillation, announced today that Joseph Pergolizzi M.D., President and Chief Executive Officer will be presenting at the U.S. MedTech Innovator 2021 Road Tour scheduled for Wednesday, March 8, via Zoom. This will be an engaging event where Dr. Pergolizzi will present in a small group setting to multiple rounds of judges during a three (3) hour session.
“We are grateful to the MedTechInnovator selection committee. We are always happy to showcase our technology, and U.S MedTech Innovator 2021 Road Tour is another in a series of opportunities we have been chosen for to present our innovative means of addressing postoperative atrial fibrillation,” Executive VP, Gary Dixon said.
MedTech Innovator is an industry’s premier global competition and the largest accelerator of medical technology in the world. They seek outstanding pre-Seed to Series C medical device, diagnostic, and digital health companies who are transforming healthcare. Their best-in-class 340 alumni now have 74 products on the market, 11 acquisitions, and raised over $2B in follow-on funding.
Native Cardio will have the chance to win up to $500,000 in non-dilutive cash awards, gain access to leadership at our corporate partners, and be exclusively featured in showcases at premier conferences in 2021 – the Wilson Sonsini Medical Device Conference and AdvaMed’s The MedTech Conference.
About Native Cardio, Inc.
Native Cardio, Inc., is a cardiac medical device manufacturer located in Naples, FL. We developed a technology that addresses a critical unmet need that often manifests following cardiovascular, thoracic, and abdominal surgery. We are referring to postoperative atrial fibrillation (POAF). POAF is highly prevalent, must treat cardiac condition. Our patented technology utilizes a novel approach to deliver low energy cardioversion and/or antiarrhythmic drugs directly to the atrial heart tissue. The system is cost-efficient, reduces expenditures, and offers an effective and precise treatment solution without the severe side effects often associated with current treatment options.
Native has been accepted into the prestigious Texas Medical Center Accelerator program (TMCx). One hundred and seventy (170) companies applied, but only twenty-one (21) were selected to participate in their Bootcamp round. We are one of three (3) cardiology companies selected. We have since advanced into their full cohort. A copy of the TMCx press release may be found here: https://www.tmc.edu/innovation/news/tmcx-fall-2020-cohort/